Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Whilst I didn’t expect it to instantly ignite the SP, today’s news was another nudge to suggest we are making great progress behind the scenes.
It would appear we are gaining traction, on multiple fronts, with substantial, separate entities. It’s clear we are very much on the radar of the UK and US governments.
Whilst there are many hard yards still to be achieved, this mornings release again reduces the risk profile for my avacta investment.
There is some possibility we may receive an update to the tune of:
-sensitivity and specificity optimised, manufacturing progressing.
-now ramping regulatory efforts.
This could precede the mother of all rns, saying ‘we are happy to share news of specificity X, sensitivity X and regulatory approval.’
This would be meteoric.
Well done those who were in before today.
Seen this happen too many times. Irrespective of product, such sharp rises in profit can be misleading for those looking for entry.
This can hit £1 just as easy as £2.
Good luck all.
Bladey - I take your point on the presence of risk. If you review some of my posts on this BB, I have been particularly vocal on showing some realism and not getting carried away. Risk absolutely does exist and becoming emotionally attached to a stock often comes at the detriment of your wealth.
That being said, my point intended to imply that the risk profile of Avacta is now less than it was in the spring. The velocity of Covid caused many leaders to panic and make bad decisions re: Testing investment. Throughout this period, Avacta has been performing its due diligence on the value of antigen testing and developing their propriety tools.
Fast forward to the end of July, antigen Testing is now a major area of emphasis for countries globally, as to accurately identify and control the spread of the virus. To that end, I feel we are not too far away from an intersection of problem and solution. We just need to be patient as the calendar date of lift off is largely irrelevant.
Bladey - between the UK and US, whom are committing a further £80bn to tackling Covid and are publicly commenting on Avacta - what makes you think we are in a risky position?
The stars are aligning - there is a new disease which has taken months to understand. We have IP to tackle immediate testing and treatment. We haven’t even gone through a winter yet, and second waves of major lockdowns are returning the world over.
And whilst SNG is clearly a breakthrough in saving lives, it’s not going to help us effectively reopen economies.
Sorry to sound absolutely brutal, but leaders worldwide will be more concerned about economic collapse than a mortality rate as low as Covid.
always winning - it took them since March to get to here.
If today’s results don’t underpin why taking your time is crucial, nothing will.
Be patient, be humble and remember this disease is devastating the entire world. An SNG sample of 100 people is not going to signal the end of Covid globally.
Re: our neutralising therapy -
Work is continuing with Professor Bhella to further study the way in which the Affimer reagents prevent infection and Avacta is using this growing body of data actively to secure a large pharmaceutical partner to develop these potential therapeutic candidates rapidly.
That plus and LFT? This will be breathtaking.
Absolutely stunning morning for SNG holders.
It just goes to show that the Covid biotech stocks can and will rip through this apparent concrete ceiling at a moments notice.
As you can see their SP rose and then plummeted in April. They have had to play the long game, longer than we have here. I think we ought to show some humility for the work Avacta are doing and be patient.
This genuinely is going to rocket when news lands.
It would be really exciting for Novacyt should they launch an antigen Test. I think it’s clear they were able to pivot and capitalise on the war against Covid by focusing on their PCR test as early as December. As avacta shareholders, we should applaud their ability to react and deliver.
Moreover, they are keen to form partnerships. Whilst there is more than enough scope for both NCYT, AVCT et al to achieve solid capital returns, as a society we will deal with this monster faster if the industry experts collaborate.
I sold out Novacyt earlier this year and am all in on avacta re: Covid shares. It’s an exciting time for both companies.
Everyone has their own emotions and circumstances. Investors will have separate agendas and timescales, so whilst £10 may be the goal for some, £1.40 may prove to be life changing for others.
If I’m being honest, I don’t have any financial targets in kind. I’ll be monitoring progress as things develop as we have seen time and time again that Avacta has a habit of adding another string to their bow.
Of course, banking profits is always useful, I’m of the opinion that this could be a serious life changer for me if I hold my shares throughout Covid and into the R&D of cancer. So, to that end, without putting a date or target on it, long term for me now.
Jdt1990 - very exciting indeed.
I can’t see procurement signing off on one supplier alone. The risk of having a key man dependency is too vast.
I might be wrong as these are unprecedented times. Regardless, I think the world may be ready for Avacta now.
Morning all,
Hope everyone has had a good week and looking forward to the weekend.
I think it’s safe to say global leaders now understand the value of and are preparing for mass antigen testing. It’s a key breakthrough not just for shareholders within respective companies, but societies too. We are yet to see the true wrath of Covid and winter is coming, physically and metaphorically.
The 500k antigen tests per day alone in the uk is staggering. Counties around the world will also require mass and frequent supply, so there is absolutely no way that a small handful of companies can produce this.
Novacyt teamed up with the major players to produce a testing lab earlier this year. I wouldn’t be surprised to see AVCT do something similar.
The challenge is quickly going to pivot from ‘does our test work’ to ‘can we make as many as we need’. I’m quietly confident this is where we will reap the rewards of the hard yards and cute planning done earlier this year re: Medusa 19.
As always, feet on the ground, but it’s hard not to get a little excited when when thinking rationally.
You start to make life changing returns when you successfully hold stocks for multiple legs up.
That always means seeing your position values pullback and consolidate. This is where most traders instinctively give up and move on.
Everything looks easy in hindsight!
Satllite - I’ve no issue with that.
Low volume and a reasonably stable SP, around the placing price, whilst we wait for the big news to drop is just fine.
Good to see the aggressive deramping is having a less adverse effect than desired.
A horizontal SP is never a bad thing when you are waiting on breakthrough news on 3 major fronts.
All the best.